Capabilities of CMOs offering vector production services Robust pipeline for cell and gene therapy increased strategic acquisitions

DUBLIN,, February 17, 2021 / PRNewswire / – Report “European Cellular and Gene Therapy Market – Industry Outlook and Forecast 2021-2026.” Added to’s offer.

In-depth analysis and insight into the impact data of COVID-19 included in this report on the European market for cell and gene therapy

The Europe The market for cell and gene therapy in terms of revenue is expected to grow at a CAGR of over 23% in the period 2021-2026.

The global market for cell and gene therapy is looking at significant mergers and acquisitions, product sales and new market approvals. In 2026, the market is expected to grow almost four times the current value, and approvals for new products are expected each year.

Although initial product approvals have been approved for relatively small groups of patients, the significant flow of cell and gene therapy studies for diseases such as hemophilia and various forms of blindness will be significantly expanded. In addition, Europe the market is growing steadily due to the increased availability of funds from several public and private institutes.

Increased support from regulatory bodies for product approval and quick product labels, which encourage suppliers to produce products quickly. Moreover, with over 237 companies with regenerative drugs based in Europe, the region is considered a favorite destination for the production of cell and gene therapy.

Cell market segmentation and gene therapy in Europe

The Europe The cell and gene therapy market research report includes detailed segmentation by product, end user, application, geographic location. The high potential for the treatment of several chronic diseases, which otherwise cannot be effectively treated / cured by conventional methods, encourages the growth of gene therapies. Gene therapies are considered a potential revolution in the health sciences and pharmaceutical fields.

The number of clinical trials investigating gene therapies is growing Europe, despite the limited number of products that have successfully arrived on the market. However, gene therapies show slow progress and promising treatment prospects. The high support of regulators to commercialize these products and make them accessible to patients is another important factor contributing to market growth.

Providing cellular and gene therapies requires specialized facilities, capabilities, and clinical skills. Therefore, manufacturers work together with selected treatment centers (hospitals) to establish the protocols and procedures needed to receive products and therapies. Although cell therapies represent a paradigm shift in the treatment of several incurable, chronic diseases, with lasting responses and long-term disease control measures, hospitals appear to be an ideal place to perform these procedures.

Hospitals are growing at a significant rate due to the increase in the target population in Europe. First-level hospitals have proven to be sought-after network partners for cell and gene therapy developers. They are usually located in larger population centers, have adequate financial and human resources, and value the prestige that comes with being the first drivers in an innovative treatment area.

Oncology had a share of over 30% in 2020. Although cancer treatments have evolved and suffered massive development in recent years, it is still one of the most deadly diseases people face. Traditional cancer therapies have a healing effect in the short term; however, they have side effects, which reduces the quality of life of the patient.

Cell and gene therapies for certain types of cancer promise results. Chimeric antigen receptor (CAR-) T cell therapy is one of the latest innovative immunotherapies and is evolving rapidly. CAR-T cell therapies are evolving rapidly, and many clinical trials have been established globally that have a high commercial potential for cancer treatment.

Immunotherapies based on CAR-T cells go one step further, shaping the T cells themselves to enhance the natural immune response to a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe blood cancers, which has increased market growth.

Supplier insight

Novartis, Spark Therapeutics, Amgen, Gilead Sciences and Organogenesis are leading players in Europe cell and gene therapy market. The market offers huge growth opportunities for existing and future / new players due to the presence of a large target population of patients with chronic diseases such as cancer, wound disorders, diabetic foot ulcers, CVD and other genetic disorders. Recent approvals have spurred unprecedented expansion among suppliers. Although several suppliers opt for in-house production of cell and gene therapies, a significant number of suppliers prefer independent service providers, including CMOs.

Prominent suppliers

  • Novartis
  • Spark Therapeutics
  • Amgen
  • Gilead Sciences
  • Organogenesis

Other prominent suppliers

  • APAC Biotech
  • AVITA Medical
  • bluebird bio
  • CHIESI Pharmaceuticals
  • CollPlant
  • CO.DON
  • PJSC Institute for Human Stem Cells (HSCI)
  • Medipost
  • NuVasive
  • Nipro
  • Orchard Therapeutics
  • RMS regenerative medical system
  • Orthocele
  • Osiris Therapeutics
  • Sibino GeneTech
  • Shanghai Sunway Biotech
  • Takeda Pharmaceutical Company
  • Terumo
  • Vericel

New investigative vendors in Europe

  • Adaptimmune Therapeutics
  • AgenTus Therapeutics
  • Autolus
  • Cellecits
  • Celyad
  • CombiGene
  • Freeline Therapeutics
  • Innoskel
  • PsiOxus Therapeutics Ltd
  • SparringVision
  • uniQure

Key topics:

1 Research methodology

2 Research goals

3 Research process

4 Scope and coverage
4.1 Market definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base year
4.3 Scope of the study
4.3.1 Market segmentation by product
4.3.2 Market segmentation by application
4.3.3 Market segmentation by end users
4.3.4 Geographic market segmentation

5 Reporting assumptions and warnings
5.1 Key remarks
5.2 Currency conversion
5.3 Market derivation

6 Market at a glance

7 Introduction
7.1 Overview

8 Market opportunities and trends
8.1 CMO offering vector production services
8.2 Robust pipeline for cell and gene therapy
8.3 Increasing strategic acquisitions

9 Market growth facilitators
9.1 Regulatory support for the cell and gene therapy market
9.2 Increased demand for CAR-T therapy in Europe
9.3 Product Launch and Approval

10 Market restrictions
10.1 Effect of COVID-19 on cellular and genetic therapy products
10.2 Increasing pressure for cell and gene therapy products
10.3 Limitations of Gene Therapy Products

11 Market landscape
11.1 Market overview
11.2 Market size and forecast
11.3 Analysis of five forces
11.3.1 Threat of new entrants
11.3.2 Bargaining power of suppliers
11.3.3 Bargaining power of customers
11.3.4 Threat of substitutions
11.3.5 Competitive rivalry

12 Product
12.1 Snapshot and market growth
12.2 Market overview
12.3 Cell therapy
12.3.1 Market overview
12.3.2 Market size and forecast
12.4 Gene therapy
12.4.1 Market overview
12.4.2 Market size and forecast

13 Application
13.1 Snapshot and market growth
13.2 Market overview
13.3 Oncology
13.4 Dermatology
13.5 Musculoskeletal
13.6 Other

14 End users
14.1 Snapshot and market growth
14.2 Market overview
14.3 Hospitals
14.4 Cancer Protection Centers
14.5 Wound Care Centers
14.6 Other

15 Geography
15.1 Snapshot and market growth
15.2 Geographical overview

For more information on this report, visit

Media contact:

Research and markets
Laura Wood, Senior Manager
[email protected]

For EST business hours, call + 1-917-300-0470
For a free call from the US / CAN + 1-800-526-8630
For GMT opening hours call + 353-1-416-8900

American Fax: 646-607-1904
Fax (outside the US): + 353-1-481-1716

SOURCE Research and Markets

Related links